Bibliografia UJ CM

1/2
Peter Hillmen, Aleksander Skotnicki, Tadeusz Robak, Branimir Jaksic, Cynthia Sirard, Jiri Mayer.
Alemtuzumab (CAMPATH, MABCAMPATH) has superior progression free survival (PFS) vs Chlorambucil as front -line therapy for patients with progressive B-cell chronic lymphocytic leukemia (BCLL).
Blood
2006 : Vol. 108, nr 11 Part 1, s. 93a, abstr. 301
American Society of Hematology Forty-eight annual meeting, Orlando, Florida, December 9-12, 2006.
SZZ
SIF
2/2
Peter Hillmen, Aleksander B. Skotnicki, Tadeusz Robak, Jiri Mayer, Branimir Jaksic, Vojo Vukovic, Steven Weitman.
Preliminary safety and efficacy report of a randomized trial of alemtuzumab vs chlorambucil as front-line therapy in 297 patients with progressive B-Cell chronic lymphocytic leukemia.
Blood
2004 : Vol. 104, nr 11 Part 1, s. 687a, abstr. 2505
American Society of Hematology Forty-six annual meeting, San Diego, California, December 4-7, 2004.
SZZ
SIF
Wyświetl ponownie stosując format:

Wyświetl/ukryj etykiety | Wyświetlenie wyników w wersji do druku | Pobranie pliku do edytora | Nowe wyszukiwanie | Biblioteka Medyczna UJ